ePharmaSolutions Launches New Application to Streamline Single Sign-On and User Account Provisioning for Sponsors Using Multiple Clinical Trial Technologies
One of the more cumbersome tasks for study teams is to manage the user administration and provisioning process into all of the technologies used to conduct clinical trials today. ePharmaSolutions has developed a solution to streamline this process to one set of credentials and one technology solution regardless of the number of vendors involved in a given study.
"The Vendor Integration Manager (VIM) is now being used on dozens of studies and provides study teams with a single user interface to manage the user provisioning process," stated Lance Converse, ePharmaSolutions founder and CEO. "Our clients complained about the need to complete up to 10 different spreadsheets each time a user is added or edited through the study, which on large studies is a difficult task that is ridden with errors," Converse added.
A typical clinical study can require up to 10 unique technology vendors that each has their own account activation and user provisioning forms and processes. This is cumbersome for clinical study managers conducting large studies who are required to complete these forms each time a user is added or edited throughout a study. For larger studies, access control to as many as 4,000 unique users in 10 systems with different roles and naming conventions must be maintained and updated in a validated environment.
"The Vendor Integration Manager works as the system of record for each user in the study and auto-completes each technology vendor's user account provisioning forms in the exact format and process they require saving study teams an enormous amount of time and avoiding countless mistakes," Converse said.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
